We assessed the potential impact of the European Union (EU) Clinical Trials Directive (CTD) on studies of investigational medicinal products (IMPs) in healthy volunteers using data from our studies in 1993–2001. The main outcome measures were time to approval of applications, including protocol amendments, by the research ethics committee (REC); types of study; types of study drug; and country of origin of sponsors.